Use of intravitreal triamcinolone and bevacizumab in Coats' disease with central macular edema
- نوع فایل : کتاب
- زبان : انگلیسی
- مؤلف : Michael R. R. Böhm & Constantin E. Uhlig
- چاپ و سال / کشور: 2011
Description
Background Intravitreal application of triamcinolone and bevacizumab in Coats' disease with macular edema to improve visual outcome. Methods Testing of best-corrected visual acuity (BCVA), ophthalmoscopy, optical coherence tomography, fluorescein angiography, 30° perimetry, and full-field electroretinography were performed at initial and follow-up visits. Medical treatment consisted of intravitreal injection of 1.25 mg bevazicumab and 1.25 mg triamcinolone, followed by intravitreal injections of 1.25 mg bevazicumab at weeks 4 and 10. Follow-up was 87 weeks. Results Perimetric results, including a temporal absolute scotoma and reduced electroretinographic amplitudes (photopic and scotopic conditions), did not significantly change during the follow-up, but foveal retinal thickness decreased from 505 ìm to 212 ìm, and BCVA increased from 0.3 at baseline to 1.25 and remained stable during subsequent follow-up. Conclusions Combined intravitreal treatment with bevacizumab and triamcinolone resulted in significant decrease of central retinal thickness and improved visual acuity in this case report. Severe local or systemic side-effects were not observed.
Graefes Arch Clin Exp Ophthalmol (2011) 249:1099–1101 DOI 10.1007/s00417-011-1629-5 Received: 13 November 2010 / Revised: 4 January 2011 / Accepted: 13 January 2011 / Published online: 12 February 2011
